Most of the coverage of Eli Lilly's triple-agonist has focused on one number: the headline weight loss. But if you're an Australian watching this drug make its way toward the TGA, the more useful question is what it actually feels like to take. The retatrutide side effects data from the Phase 3 TRIUMPH-1 trial is now detailed enough to answer that — and the most interesting finding isn't the side effects themselves. It's that the dose you take appears to change the trade-off dramatically.
Here's what the numbers show, and why the 4mg dose may end up mattering more to everyday Aussies than the 12mg headline.
What the TRIUMPH-1 side effect data actually shows
TRIUMPH-1 tested three doses — 4mg, 9mg and 12mg — against placebo in adults with obesity or overweight plus at least one weight-related condition. The side effect profile was, unsurprisingly, gastrointestinal.Across the 4mg, 9mg and 12mg groups compared with placebo, nausea was reported by 28.6%, 38.4% and 42.4% of retatrutide participants respectively, versus 14.8% for placebo; diarrhoea by 25.2%, 34.1% and 32.0% versus 13.5%; constipation by 23.8%, 25.9% and 26.1% versus 10.9%; and vomiting by 10.6%, 22.8% and 25.3% versus 4.8% for placebo.
Two things stand out. First, placebo participants also reported plenty of gut symptoms — meaning a meaningful slice of what people experience isn't purely drug-driven. Second, the gradient is steep. Vomiting more than doubled between 4mg and 12mg.
Adverse events were characterised as typical incretin-associated GI effects. In other words: broadly the same family of symptoms Australians already know from semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — not a new category of problem. You can read more on how the three drugs differ mechanically in our comparison of retatrutide's triple-receptor design.
Beyond the gut: dysesthesia and heart rate
Two non-GI signals deserve attention. Other observed adverse events included upper respiratory tract infections, urinary tract infections, and mild to moderate dysesthesia, although the majority of the urinary and neurological cases resolved during active treatment.
Dysesthesia is the one people haven't heard of. It's an altered sense of touch, described as burning, tingling, prickling, or skin feeling unusually sensitive to clothing, water or pressure — not pain caused by injury and not an allergic reaction. Notably, it wasn't seen in the Phase 2 trial, so its appearance at higher Phase 3 doses raised questions about what was driving it. In trials it has been reported as mild and very rarely causing a person to stop the medication.
There's also a cardiovascular note: retatrutide's side effects fall into three main groups — gut symptoms during dose increases, a heart-rate increase larger than other GLP-1 medications, and dysesthesia at higher doses in Phase 3. That heart-rate signal is one of the things Australian regulators and prescribers will be scrutinising closely. More on our safety page.
The 4mg finding: the most under-reported result in TRIUMPH-1
This is the part that deserves far more airtime than it's had.
Discontinuation is the honest measure of tolerability — it tells you how many people found the drug not worth persisting with. Discontinuation rates owing to adverse events were 4.1%, 6.9% and 11.3% with retatrutide 4mg, 9mg and 12mg respectively, compared with 4.9% with placebo.
Read that again. At 4mg, people were dropping out slightly less often than on placebo. At 12mg, more than one in ten stopped.
And the 4mg dose was not a token dose. Even the lower 4mg dose delivered an average 19.0% weight loss with fewer discontinuations due to adverse events, which matters for real-world tolerability.
Nineteen per cent average weight loss with placebo-level dropout is, by any historical standard, an extraordinary result — it sits at or above what the highest doses of earlier-generation drugs achieved. Meanwhile the top dose keeps climbing: retatrutide achieved 28.3% weight loss at 80 weeks and 30.3% at 104 weeks.
The practical implication for Australians is that "retatrutide" won't be one experience. If and when it reaches Australian pharmacies, the conversation with your GP is likely to be about which dose suits your goals and your tolerance — not simply whether you're on it. Our clinical trials hub tracks each TRIUMPH readout as it lands.
Why escalation timing matters
A consistent pattern across the incretin class is that gut symptoms cluster during dose escalation and settle at a stable maintenance dose. That's the same reason Australian prescribers titrate semaglutide and tirzepatide slowly over months. Expect retatrutide to arrive with a similarly staged titration schedule — and expect the worst weeks to be the weeks you step up.
What this means for Australians waiting on access
Retatrutide is investigational and not approved by the TGA. It cannot be prescribed in Australia today, and Eli Lilly has indicated regulatory filings from 2027 — which means an Australian launch realistically sits some way beyond that, after TGA evaluation and any PBS consideration.
That matters for how you read side effect data now. When retatrutide does reach a TGA dossier, the regulator won't just be assessing whether the drug works — it'll be weighing dose-by-dose risk against dose-by-dose benefit. A drug that delivers 19% weight loss with placebo-level discontinuation gives regulators a much easier decision than one that only exists at its most aggressive dose.
With TRIUMPH-2 in patients with type 2 diabetes and TRIUMPH-3 in patients with established cardiovascular disease expected later this year, the safety picture will keep filling in across very different patient groups — including people with existing heart disease, where that heart-rate signal will be tested properly.
For context on where Australia sits in the global queue, see our Australia access page.
The honest summary
Retatrutide's side effects are real, dose-dependent, and mostly familiar to anyone who has followed the GLP-1 story. The novel signal — dysesthesia — appears mild and largely reversible on treatment, but it's genuinely new and warrants ongoing scrutiny. The heart-rate increase is the item to watch most closely.
The headline you probably haven't seen: the lowest dose tested delivered life-changing weight loss with tolerability indistinguishable from placebo. That's the finding that could ultimately determine how many Australians actually stay on this drug.
Want the TRIUMPH-2 and TRIUMPH-3 safety data the day it drops? Join our free Australian updates list — no cost, no spam, just the regulatory and trial milestones that matter.
FAQ
What are the side effects of retatrutide?
The most common are gastrointestinal. In TRIUMPH-1, nausea was reported by 28.6% to 42.4% of participants depending on dose (versus 14.8% on placebo), with diarrhoea, constipation and vomiting also common. Some participants also reported dysesthesia — unusual skin sensations such as tingling or burning.
Are retatrutide's side effects worse than Ozempic or Mounjaro?
They're from the same family of incretin-related gut symptoms, and TRIUMPH-1 adverse events were described as typical incretin-associated effects. The differences are that retatrutide showed a heart-rate increase larger than other GLP-1 medications, plus dysesthesia at higher doses, and that its side effects scale noticeably with dose.
Do retatrutide side effects go away over time?
Across the incretin class, gut symptoms are typically worst during dose escalation and ease once a stable maintenance dose is reached. In TRIUMPH-1, the majority of urinary and neurological adverse events resolved during active treatment. Individual experience varies considerably.
Is retatrutide available in Australia yet?
No. Retatrutide is investigational and has not been approved by the TGA, so it cannot be legally prescribed in Australia. Eli Lilly has signalled regulatory filings from 2027, with any Australian availability following TGA evaluation after that.
Disclaimer: This article is general information only and is not medical advice. Retatrutide is an investigational medicine that is not approved by the Therapeutic Goods Administration (TGA) and is not available on prescription in Australia. Individual side effects and outcomes vary. Always speak to your GP or a qualified Australian health professional about weight management options suitable for you. retatrutide.net.au is an independent information resource and is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or any pharmaceutical manufacturer.
